Drug archive
Bortezomib (Systemic)
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Category
- Antineoplastic
Description
Bortezomib ((bor-TEZ-oh-mib)) belongs to the general group of medicines known as antineoplastics. It is used to treat multiple myeloma in patients who have received other treatments that have not helped.
Bortezomib interferes with the growth of cancer cells, which are then eventually destroyed by the body. Since the growth of normal body cells may also be affected by bortezomib, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects may not be serious but may cause concern. Some effects may not occur until months or years after the medicine is used.
Bortezomib is to be administered only by or under the supervision of your doctor. It is available in the following dosage form:
- Injection U.S.
Brand Names
Some commonly used brand names are:
In the U.S. -
- Velcade
† Not commercially available in Canada.